Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor.
Guo-Ying LiuNian LuWei-Xin BeiWang-Zhong LiHu LiangWei-Xiong XiaYan-Qun XiangHe-Rui Yao
Published in: Frontiers in immunology (2023)
Our novel prognostic model was able to stratify patients with metastatic NPC into low-risk or high-risk groups and identify candidates for PD-1 inhibitor therapy. These results are expected to be confirmed by a prospective clinical trial.